Dustin S. Sjuts - 15 Dec 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
President
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Dec 2023
Net transactions value
-$38,073
Form type
4
Filing time
18 Dec 2023, 16:32:22 UTC
Previous filing
15 Aug 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $38,073 -4,712 -2.9% $8.08 157,354 15 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 11,973 shares. The RSA vests in three equal annual installments from December 15, 2021.